BridgeBio 药

最新新闻

• CCORF Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  William Blair Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Raises Target Price to $93
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• RBC Capital Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $104 to $156
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $93
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $94 to $115
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $110 to $157
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $97 to $115
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $94 to $157
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $101
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
  TipRanks · 2026/8/12
• H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $96
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• BridgeBio (BBIO.US) cardiac therapy acoramidis outperforms Pfizer’s (PFE.US) competitor drug in real-world study
  Zhitong Finance · 2026/9/24
• 评级变动
  H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  RBC Capital Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。